Is IDIX a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

1,027 people get IDIX articles and Market Currents by email alert.

Get email alerts on IDIX »

HEADLINES:

Idenix Pharmaceuticals' CEO Presents at UBS Global Healthcare Services Conference (Transcript)
Tue, May 21
Idenix Pharmaceuticals' CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)
Wed, May 15
Complete Seth Klarman And Baupost Group Portfolio Update
Profit Fan • Wed, May 15 • 3 Comments
Tracking Seth Klarman's Baupost Group Holdings - Q1 2013 Update
John Vincent • Wed, May 15 • 3 Comments
Seth Klarman's Worst Performing Stock Picks Year-To-Date
Profit Fan • Mon, May 13 • 11 Comments
Idenix Pharmaceuticals to Present at Three Upcoming Healthcare Conferences

GlobeNewswire (May 8, 2013)
Predicting Biotech Stock Moves Using Top Consensus Picks By Legendary Fund Managers
GuruFundPicks • Sun, May 5 • 3 Comments
Idenix Pharmaceuticals Reports First Quarter 2013 Financial Results

GlobeNewswire (Apr 30, 2013)
Idenix Reports Favorable Resistance Profile for IDX719, a Potent, Pan-Genotypic HCV NS5A Inhibitor, at EASL Meeting

GlobeNewswire (Apr 24, 2013)
Achillion: Moving Beyond Sofosbuvir's Shadow
PropThink • Tue, Apr 16 • 1 Comment
Idenix Announces Data Presentation at the 48th Annual Meeting of the European Association for the Study of the Liver (EASL)

GlobeNewswire (Apr 8, 2013)
Idenix Pharmaceuticals' CEO Hosts Patent Interference Update Conference (Transcript)
Mon, Mar 25
Idenix Pharmaceuticals Announces Decision by the United States Patent and Trademark Office Patent Trial and Appeal Board in the First Phase of the Interference

GlobeNewswire (Mar 22, 2013)
The Stem Cell Revolution Can Jump Start Your Portfolio: Jason Kolbert
Life Sciences Report • Fri, Mar 15 • 16 Comments
Idenix's Management Presents at Barclays Global Healthcare Conference (Transcript)
Wed, Mar 13 • 3 Comments
Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences

GlobeNewswire (Feb 26, 2013)
Idenix Pharmaceuticals Reports Fourth Quarter and Year Ended 2012 Financial Results

GlobeNewswire (Feb 25, 2013)
A Review Of Seth Klarman's Baupost Group's Q4 U.S. Equity Changes
Zvi Bar • Mon, Feb 18 • 3 Comments
Tracking Seth Klarman's Baupost Group Holdings - Q4 2012 Update
John Vincent • Thu, Feb 14 • 2 Comments
Idenix Pharmaceuticals' CEO Presents at Update on IDX184 and IDX19368 Development Programs Conference (Transcript)
Tue, Feb 5

To learn more about Seeking Alpha Pro, click here.

New Second Generation Combination Therapy For HCV - First Or Best In The Market - Part 3
LifeSci Advisors • Fri, Nov 30, 2012 • 3 Comments
Idenix And The High-Stakes Ping-Pong Of Hep C Treatments
Stephen Simpson • Thu, Aug 16, 2012 • 2 Comments
Is The Hep C Drug Pipeline Beginning To Crack?
Bioassociate Consulting • Thu, Aug 16, 2012 • 2 Comments
Idenix: New HCV Drug Could Be A Blockbuster
Cris Frangold • Tue, Jul 3, 2012 • 5 Comments
Positive Data Released On Idenix Pharmaceuticals IDX184 Hep C Drug
EXPstocktrader • Tue, Jun 19, 2012 • 5 Comments
Idenix Pharmaceuticals: A Hepatitis C Play Revisited
EXPstocktrader • Tue, Jun 12, 2012
Idenix Will Move Up On Promising New Data In 2013
Vatalyst • Fri, May 11, 2012 • 3 Comments
Idenix Pharmaceuticals: Go Short Or Bet Long With The Insiders?
M. E. Garza • Tue, Dec 6, 2011 • 3 Comments
Expecting Weakness In Idenix Pharma Following Piper Note
Notable Calls • Fri, Feb 23, 2007

Complete Seth Klarman And Baupost Group Portfolio Update
Profit Fan • Wed, May 15 • 3 Comments
Tracking Seth Klarman's Baupost Group Holdings - Q1 2013 Update
John Vincent • Wed, May 15 • 3 Comments
Seth Klarman's Worst Performing Stock Picks Year-To-Date
Profit Fan • Mon, May 13 • 11 Comments
Predicting Biotech Stock Moves Using Top Consensus Picks By Legendary Fund Managers
GuruFundPicks • Sun, May 5 • 3 Comments
Achillion: Moving Beyond Sofosbuvir's Shadow
PropThink • Tue, Apr 16 • 1 Comment
The Stem Cell Revolution Can Jump Start Your Portfolio: Jason Kolbert
Life Sciences Report • Fri, Mar 15 • 16 Comments
A Review Of Seth Klarman's Baupost Group's Q4 U.S. Equity Changes
Zvi Bar • Mon, Feb 18 • 3 Comments
Tracking Seth Klarman's Baupost Group Holdings - Q4 2012 Update
John Vincent • Thu, Feb 14 • 2 Comments
Why You Should Sell Vertex
Rx Stocks • Mon, Jan 21 • 16 Comments
3 Highly Shorted Stocks Under $5 Being Snapped Up By Hedge Funds
Kapitall • Tue, Jan 15
Biotech Weekly Recap: Loads Of Bullishness, 2 Giant Rallies, And Selling
Brian L. Wilson • Sun, Dec 2, 2012 • 19 Comments
Lessons From The Liver Meeting: Sagient's John Tucker Names Companies That Could Reignite The Hepatitis C Industry
Life Sciences Report • Fri, Nov 30, 2012 • 3 Comments
7 Biotech Stocks Trading At Steep Discount To Target Price
Kapitall • Thu, Nov 15, 2012
Tracking Seth Klarman's Baupost Group Holdings - Q3 2012 Update
John Vincent • Wed, Nov 14, 2012
5 High-Growth Biotech Stocks With Bearish Short Trends
Kapitall • Mon, Nov 5, 2012 • 7 Comments
Recent Biotech Price Dips Make Great Entries For Investors
Brian Nichols • Thu, Nov 1, 2012 • 15 Comments
Players In Hepatitis C Treatment Market Officially In Play
Stock Traders Daily • Fri, Oct 19, 2012 • 3 Comments
Tracking The Investment Profile Of A Proven Winner
Scott Matusow • Tue, Sep 25, 2012 • 15 Comments
Medgenics' Bulging Pipeline Of Blockbuster Indications Takes On Big Pharma's Harmful Drugs
Ray Dirks • Tue, Sep 18, 2012 • 8 Comments
Tuesday's 10 Most Tweeted Stocks
Contextuall • Wed, Aug 29, 2012 • 2 Comments

Idenix Pharmaceuticals' CEO Presents at UBS Global Healthcare Services Conference (Transcript)
Tue, May 21
Idenix Pharmaceuticals' CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)
Wed, May 15
Idenix Pharmaceuticals' CEO Hosts Patent Interference Update Conference (Transcript)
Mon, Mar 25
Idenix's Management Presents at Barclays Global Healthcare Conference (Transcript)
Wed, Mar 13 • 3 Comments
Idenix Pharmaceuticals' CEO Presents at Update on IDX184 and IDX19368 Development Programs Conference (Transcript)
Tue, Feb 5
Idenix Pharmaceuticals CEO Presents at 31st Annual JPMorgan Healthcare Conference (Transcript)
Wed, Jan 9 • 1 Comment
Idenix Pharmaceuticals' CEO Presents at 2012 Deutsche Bank Access BioFEST Conference (Transcript)
Mon, Dec 3, 2012 • 2 Comments
Idenix Pharmaceuticals' CEO Discusses Q3 2012 Results - Earnings Call Transcript
Thu, Nov 1, 2012
Idenix Pharmaceuticals' CEO Presents at UBS 2012 Global Life Sciences Conference (Transcript)
Thu, Sep 20, 2012
Idenix Pharmaceuticals' CEO Presents at Morgan Stanley Global Healthcare Conference (Transcript)
Mon, Sep 10, 2012
Idenix Pharmaceuticals' CEO Provides Update on IDX184 Clinical Development Program Conference (Transcript)
Fri, Aug 17, 2012 • 1 Comment
Idenix Pharmaceuticals' CEO Presents Restructuring of Development and Commercialization Collaboration With Novartis Pharma AG Call (Transcript)
Wed, Aug 1, 2012
Idenix Pharmaceuticals' CEO Presents at Deutsche Bank 37th Annual Healthcare Conference (Transcript)
Mon, May 7, 2012
Idenix Pharmaceuticals, Inc. Q2 2010 Earnings Call Transcript
Mon, Jul 26, 2010
Idenix Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript
Mon, May 3, 2010
Idenix Pharmaceuticals, Inc. Q4 2008 Earnings Call Transcript
Tue, Feb 17, 2009
Idenix Pharmaceuticals, Inc. Q3 2008 Earnings Call Transcript
Mon, Nov 17, 2008
Idenix Pharmaceuticals, Inc. Q2 2008 Earnings Call Transcript
Tue, Jul 29, 2008
Idenix Pharmaceuticals Inc. Q1 2008 Earnings Call Transcript
Tue, Apr 29, 2008
Idenix Pharmaceuticals Inc. Q4 2007 Earnings Call Transcript
Thu, Mar 6, 2008

Idenix Pharmaceuticals to Present at Three Upcoming Healthcare Conferences

GlobeNewswire (May 8, 2013)
Idenix Pharmaceuticals Reports First Quarter 2013 Financial Results

GlobeNewswire (Apr 30, 2013)
Idenix Reports Favorable Resistance Profile for IDX719, a Potent, Pan-Genotypic HCV NS5A Inhibitor, at EASL Meeting

GlobeNewswire (Apr 24, 2013)
Idenix Announces Data Presentation at the 48th Annual Meeting of the European Association for the Study of the Liver (EASL)

GlobeNewswire (Apr 8, 2013)
Idenix Pharmaceuticals Announces Decision by the United States Patent and Trademark Office Patent Trial and Appeal Board in the First Phase of the Interference

GlobeNewswire (Mar 22, 2013)
Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences

GlobeNewswire (Feb 26, 2013)
Idenix Pharmaceuticals Reports Fourth Quarter and Year Ended 2012 Financial Results

GlobeNewswire (Feb 25, 2013)
Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences

GlobeNewswire (Feb 5, 2013)
Idenix Pharmaceuticals Provides Update on IDX184 and IDX19368 Development Programs

GlobeNewswire (Feb 4, 2013)
Idenix Pharmaceuticals Announces Collaboration With Janssen to Initiate Phase II All-Oral Combination Studies Including IDX719, Simeprevir (TMC435) and TMC647055 for the Treatment of Hepatitis C Virus (HCV)

GlobeNewswire (Jan 28, 2013)
Idenix Pharmaceuticals to Present at the 31st Annual J.P. Morgan Healthcare Conference

GlobeNewswire (Jan 2, 2013)
Idenix Pharmaceuticals to Present at the Oppenheimer 23rd Annual Healthcare Conference

GlobeNewswire (Dec 5, 2012)
Midday Movers: AEO, ANN, KCG & More

at CNBC.com (Nov 28, 2012)
Idenix Pharmaceuticals to Present at the 2012 Deutsche Bank Access BioFEST Conference

GlobeNewswire (Nov 26, 2012)
Idenix Pharmaceuticals Reports Clinical Data for HCV Drug Candidates - IDX719 and IDX184 - at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting

GlobeNewswire (Nov 10, 2012)
Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2012 Financial Results and HCV Program Update

GlobeNewswire (Nov 1, 2012)
Idenix to Host Conference Call Discussing Third Quarter and Nine Month 2012 Financial Results and HCV Program Update

GlobeNewswire (Oct 25, 2012)
Movers & Shakers: Wednesday’s biggest gaining and declining stocks

at MarketWatch.com (Sep 19, 2012)
Stocks to Watch: WYNN, QCOR, CBRL & More

at CNBC.com (Sep 19, 2012)
Idenix Pharmaceuticals to Present at the UBS Global Life Sciences Conference

GlobeNewswire (Sep 13, 2012)

IDIX vs. ETF Alternatives

Company Description

Currently, there's no company description for IDIX.

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, May 15, 11:50 AM Seth Klarman added two new positions to Baupost in Q1, with Elan (ELN) now 3.5% of his portfolio and DirecTV (DTV) 0.38%. He added to already major positions in BP, AIG, ROVI, and IDIX, and completely sold out of GNW, and ANV. 1 Comment
Monday, March 25, 12:47 PM Midday top 10 gainers: STXS +56%. VBFC +14%. LEDS +13%. ERII +11%. VECO +11%. HZNP +10%. APOL +10%. SRT +10%. GSV +10%. EQU +9%.
Midday top 10 losers: PGTI -16%. IDIX -15%. JASO -13%. TSL -13%. TOPS -13%. VHC -11%. FREE -10%. JE -10%. YGE -10%. BWEN -10%. Comment! [On the Move]
Monday, March 25, 11:52 AM Idenix Pharmaceuticals (IDIX -12.6%) slips back near its lows for the day, after the USPTO decided against it late Friday in the first phase of a two-stage interference process regarding the biopharmaceutical company's patent applications for certain compounds for treating hepatitis C. Comment! [Healthcare, On the Move]
Monday, March 25, 9:10 AM Premarket gainers: ZAZA +21%. ARWR +14%. APOL +9%. TSRX +5%. Losers: IDIX -10%. OTT -10%. UTHR -7%. PGTI -6%. Comment! [On the Move]
Friday, March 22, 6:01 PM Idenix Pharmaceuticals (IDIX) says the USPTO's Patent Trial and Appeal Board has decided against it in the first phase of its two-stage interference process concerning one of IDIX's patent applications, and an issued patent owned by Gilead Pharmasset (GILD) that covers certain 2'-methyl- 2'-fluoro nucleoside compounds useful in the treatment of the hepatitis C virus. Shares -13% AH. Comment! [Healthcare, On the Move]
Friday, March 22, 5:44 PM After-hours top gainers, as of 5:15 p.m.: SFD +6%. REGI +6%. GTI +4%. FIVE +4%. KWK +4%.
After-hours top losers: IDIX -10%. TTS -6%. SVU -4%. MTG -3%. ARNA -2%. 3 Comments [On the Move]
Wednesday, February 27, 5:46 PM After-hours top gainers, as of 5:15 p.m.: BWC +9%. ARAY +4%. IDIX +4%. CLDX +3%. UAN +3%.
After-hours top losers: GRPN -25%. BSFT -23%. ANW -14%. VCRA -12%. JCP -9%. 3 Comments [On the Move]
Monday, February 25, 4:59 PM More on Idenix Pharmaceuticals (IDIX) Q4 comes in below revenue estimates, despite a 141% Y/Y jump in sales. EPS were Up 6% from the same quarter last year. Revenue came in at $300.0K versus the estimated $740.0K . Sales were Up 141% year over year. Comment! [Healthcare, Earnings]
Monday, February 25, 4:53 PM Idenix Pharmaceuticals (IDIX): Q4 EPS of -$0.17 in-line. Revenue of $327K misses by $410M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Friday, February 8, 5:43 PM After-hours top gainers, as of 5:15 p.m.: WR +5%. IDIX +3%. MTG +2%. GOL +2%. MTGE +2%.
After-hours top losers: MERU -3%. ROC -2%. MELI -2%. BG -2%. INFN -2%. Comment! [On the Move]
Tuesday, February 5, 10:33 AM Idenix (IDIX -0.6%) regains some of yesterday's post-session dip, but still trails the overall market after saying that it's discontinuing its clinical development program for two of its investigational hepatitis C drugs, after the FDA said the treatments would remain on clinical hold. The hold is related to the regulator's heart-safety concerns about rival Bristol-Myers Squibb's (BMY) BMS-986094, a treatment for the liver disease which belongs to the same class of drugs known as nucleotide polymerase inhibitors. Comment! [Healthcare, On the Move]
Monday, February 4, 5:47 PM After-hours top gainers, as of 5:15 p.m.: JNY +5%. EDMC +5%. BRKS +5%. MM +5%. GFF +4%.
After-hours top losers: PC -10%. IDIX -7%. RTEC -6%. YUM -6%. BIDU -5%. Comment! [On the Move]
Monday, January 28, 12:09 PM Idenix Pharmaceuticals (IDIX +11.4%) pops this morning after saying it's entered into a non-exclusive collaboration with Janssen Pharmaceuticals for the clinical development of antiviral Hepatitis C vaccine combination therapies. The plans include an initial drug-drug interaction study to begin in the first quarter of 2013, followed by phase II studies pending approval from regulatory authorities. Comment! [Healthcare, On the Move]
Wednesday, December 26, 2012, 5:57 PM After-hours top gainers, as of 5:30 p.m.: MACK +5%. CLDX +4%. FOLD +4%. IDIX +3%. NBIX +2%.
After-hours top losers: AMBA -2%. DGAZ -2%. MRVL -2%. DNDN -2%. PRSS -1%. 1 Comment [On the Move]
Wednesday, November 28, 2012, 5:42 PM After-hours top gainers, as of 5:15 p.m.: BLOX +17.2%. SMTC +7.6%. GES +5.2%. ARQL +4.7%. WDAY +3.8%.
After-hours top losers: IDIX -14.7%. LZB -13.3%. TKR -10.4%. ARO -7.2%. VECO -7.1%. Comment! [On the Move]
Wednesday, November 28, 2012, 2:35 PM Idenix Pharmaceuticals (IDIX +16.6%) moves up today after being initiated with a Buy at Deutsche Bank. The firm says the Street is undervaluing IDIX's new drug pipeline, as investors have been spooked since the FDA put a clinical trials of its lead hepatitis C candidate on hold in August. IDIX recently said study data showed the drug is safe and cured 82% of patients, and the agency's decision on lifting the hold - expected early 2013 - is the key event for the stock. Comment! [Healthcare, On the Move]

John Vincent
Seth Klarman of Baupost Group added $AIG and eliminated $HPQ. Also added to $IDIX and reduced $ORCL & $ANV : http://seekingalpha.com/a/pcoz
Feb 14, 6:00 AM
Reply (2)

• !Report Abuse
View all 2 replies
pundr: $AIG everyone buys AIG. Great!!!! Long Term when the grow their book value. A very strong and safe stock.
Feb 14, 6:52 AM
• !Report Abuse
inandoutnevertoolate: surprised AIG is under-performing today. Bought on the close yesterday, thinking I was getting it cheap for a day-trade. May double up soon.
Feb 14, 10:47 AM
• !Report Abuse
Add a reply...

140 characters

Alex Jantsch
Seth Klarman's Baupost Group announces 12% stake in IDIX... http://bit.ly/SI1ZD7
11/12/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

freefdawatchlist
ttp://http://bit.ly/SQ3pfp Premaket Gainer & Loser: $PCP, $JEF, $CXS, $IDIX, $CLVS
11/12/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

freefdawatchlist
http://stks.co/fBP2 Premarket loser $IDIX, $GTAT, $KLAC, $LRCX, Premarket gainer $ACHN, $CY, $DRYS, $CBRL
9/19/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
3 Analyst Endorsed Small Cap Biotech Stocks Slated For Growth http://bit.ly/N684rX $AFFY $IDIX $SQNM @ZetaKap
8/2/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

freefdawatchlist
http://bit.ly/Le0Bda Premarket gainer IDIX(14%), TSLA(4%), STSI(4%), ARNA(4%), oser RMTI(6.5%), ADBE(6%), CETV(4%), ATPG(3%)
6/20/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Cockrell Group
Credit Suisse analyst Ravi Mehrotra starts coverage on: $VRTX, $ACHN, $MVIR'B-SFYK.PK, $IDIX http://bit.ly/HR3EXn
4/17/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Tony Kau
$IDIX a keen buy - TrendExhaustion score: 7 http://bit.ly/J6LZEE
4/13/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

tradingblues1
Check out IDIX. It's getting hammered today
4/4/12
Reply (1)

• !Report Abuse
View all 1 replies
Windsun33: Yeah, but still at around 3x it's 52 week low, had a big runup not long ago.
4/4/12
• !Report Abuse
Add a reply...

140 characters

StockPandit
IDIX moving up nicely today
4/3/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

John Vincent
Seth Klarman of Baupost Group added $AIG and eliminated $HPQ. Also added to $IDIX and reduced $ORCL & $ANV : http://seekingalpha.com/a/pcoz
Feb 14, 6:00 AM
Reply (2)

• !Report Abuse
View all 2 replies
pundr: $AIG everyone buys AIG. Great!!!! Long Term when the grow their book value. A very strong and safe stock.
Feb 14, 6:52 AM
• !Report Abuse
inandoutnevertoolate: surprised AIG is under-performing today. Bought on the close yesterday, thinking I was getting it cheap for a day-trade. May double up soon.
Feb 14, 10:47 AM
• !Report Abuse
Add a reply...

140 characters

tradingblues1
Check out IDIX. It's getting hammered today
4/4/12
Reply (1)

• !Report Abuse
View all 1 replies
Windsun33: Yeah, but still at around 3x it's 52 week low, had a big runup not long ago.
4/4/12
• !Report Abuse
Add a reply...

140 characters

FortSumter
Playing the bitotech lottery with a play on IDIX. Buy out by MRK maybe? Big month ahead.
2/13/12
Reply (13)

• !Report Abuse
View all 13 replies
John Rayhall: IDIX has a huge buyout premium in already was 7 before the INHX buyout. Any bad news and it'll get crushed.
2/23/12
• !Report Abuse
John Rayhall: Nice trading :)
2/23/12
• !Report Abuse
Add a reply...

140 characters

John Rayhall
Holy cow! What a reversal in IDIX in a matter of minutes I guess youc an;t keep a good buyout candidate down! lol glad I bought some at13.08
1/27/12
Reply (1)

• !Report Abuse
View all 1 replies
John Rayhall: *can't
1/27/12
• !Report Abuse
Add a reply...

140 characters

IDIX Idenix Pharmaceuticals, Inc.

IDIX

Idenix Pharmaceuticals, Inc.